{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:51:09Z","timestamp":1793757069603,"version":"4.6.1"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100016516","name":"Comprehensive Cancer Center, University of Chicago Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016516","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA014599"],"award-info":[{"award-number":["P30 CA014599"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1R01CA216436"],"award-info":[{"award-number":["1R01CA216436"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1R01CA223184"],"award-info":[{"award-number":["1R01CA223184"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomaterials"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.biomaterials.2021.121315","type":"journal-article","created":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T05:32:47Z","timestamp":1639027967000},"page":"121315","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":102,"special_numbering":"C","title":["Co-delivery of dihydroartemisinin and pyropheophorbide-iron elicits ferroptosis to potentiate cancer immunotherapy"],"prefix":"10.1016","volume":"280","author":[{"given":"Wenbo","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8713-6773","authenticated-orcid":false,"given":"Xiaopin","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8152-6746","authenticated-orcid":false,"given":"Kaiyuan","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8185-4750","authenticated-orcid":false,"given":"Youyou","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7035-7759","authenticated-orcid":false,"given":"Wenbin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6382","key":"10.1016\/j.biomaterials.2021.121315_bib1","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"issue":"6382","key":"10.1016\/j.biomaterials.2021.121315_bib2","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"issue":"6230","key":"10.1016\/j.biomaterials.2021.121315_bib3","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"issue":"328","key":"10.1016\/j.biomaterials.2021.121315_bib4","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad7118","article-title":"PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations","volume":"8","author":"Zou","year":"2016","journal-title":"Sci. Transl. Med."},{"issue":"7528","key":"10.1016\/j.biomaterials.2021.121315_bib5","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","journal-title":"Nature"},{"issue":"7528","key":"10.1016\/j.biomaterials.2021.121315_bib6","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.biomaterials.2021.121315_bib7","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1158\/2159-8290.CD-15-0563","article-title":"Adaptive immune resistance: how cancer protects from immune attack","volume":"5","author":"Ribas","year":"2015","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.biomaterials.2021.121315_bib8","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.coi.2013.02.009","article-title":"Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment","volume":"25","author":"Gajewski","year":"2013","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.biomaterials.2021.121315_bib9","doi-asserted-by":"crossref","first-page":"5692","DOI":"10.1126\/sciimmunol.aan5692","article-title":"A melanin-mediated cancer immunotherapy patch","volume":"2","author":"Ye","year":"2017","journal-title":"Sci. Immunol"},{"key":"10.1016\/j.biomaterials.2021.121315_bib10","doi-asserted-by":"crossref","first-page":"1806957","DOI":"10.1002\/adma.201806957","article-title":"A dual\u2010bioresponsive drug\u2010delivery depot for combination of epigenetic modulation and immune checkpoint blockade","author":"Ruan","year":"2019","journal-title":"Adv. Mater."},{"issue":"9528","key":"10.1016\/j.biomaterials.2021.121315_bib11","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/S0140-6736(06)68931-9","article-title":"Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparison","volume":"367","author":"Smithuis","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.biomaterials.2021.121315_bib12","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3389\/fonc.2014.00116","article-title":"Dihydroartemisinin is a hypoxia-active anti-cancer drug in colorectal carcinoma cells","volume":"4","author":"Ontikatze","year":"2014","journal-title":"Frontiers in oncology"},{"issue":"23","key":"10.1016\/j.biomaterials.2021.121315_bib13","doi-asserted-by":"crossref","first-page":"10854","DOI":"10.1158\/0008-5472.CAN-05-1216","article-title":"Dihydroartemisinin is cytotoxic to papillomavirus-expressing epithelial cells in vitro and in vivo","volume":"65","author":"Disbrow","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.biomaterials.2021.121315_bib14","first-page":"95","article-title":"Activated oxygen mediates the antimalarial activity of qinghaosu","volume":"313","author":"Meshnick","year":"1989","journal-title":"Prog. Clin. Biol. Res."},{"issue":"8","key":"10.1016\/j.biomaterials.2021.121315_bib15","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1016\/0006-2952(92)90713-S","article-title":"Hemin-catalyzed decomposition of artemisinin (qinghaosu)","volume":"43","author":"Zhang","year":"1992","journal-title":"Biochem. Pharmacol."},{"issue":"5874","key":"10.1016\/j.biomaterials.2021.121315_bib16","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1126\/science.1155165","article-title":"Qinghaosu (artemisinin): the price of success","volume":"320","author":"White","year":"2008","journal-title":"Science"},{"issue":"8845","key":"10.1016\/j.biomaterials.2021.121315_bib17","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/0140-6736(93)90362-K","volume":"341","author":"Hien","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.biomaterials.2021.121315_bib18","series-title":"Biomedical Chemistry: Applying Chemical Principles to Understanding and Treatment of Disease","first-page":"289","article-title":"Carbon-centered radicals and rational design of new antimalarial peroxide drugs","author":"Posner","year":"2000"},{"issue":"3","key":"10.1016\/j.biomaterials.2021.121315_bib19","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1365-2125.2011.04103.x","article-title":"Artesunate\/dihydroartemisinin pharmacokinetics in acute falciparum malaria in pregnancy: absorption, bioavailability, disposition and disease effects","volume":"73","author":"McGready","year":"2012","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.biomaterials.2021.121315_bib20","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/1475-2875-10-263","article-title":"Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration","volume":"10","author":"Morris","year":"2011","journal-title":"Malar. J."},{"issue":"12","key":"10.1016\/j.biomaterials.2021.121315_bib21","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1111\/bcp.13372","article-title":"Population pharmacokinetics and electrocardiographic effects of dihydroartemisinin\u2013piperaquine in healthy volunteers","volume":"83","author":"Chotsiri","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.biomaterials.2021.121315_bib22","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.ejmech.2018.04.005","article-title":"Design, synthesis, cytotoxicity and mechanism of novel dihydroartemisinin-coumarin hybrids as potential anti-cancer agents","volume":"151","author":"Yu","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"12","key":"10.1016\/j.biomaterials.2021.121315_bib23","doi-asserted-by":"crossref","first-page":"1704007","DOI":"10.1002\/adma.201704007","article-title":"Emerging strategies of cancer therapy based on ferroptosis","volume":"30","author":"Shen","year":"2018","journal-title":"Adv. Mater."},{"issue":"1","key":"10.1016\/j.biomaterials.2021.121315_bib24","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/s41418-019-0352-3","article-title":"Artemisinin compounds sensitize cancer cells to ferroptosis by regulating iron homeostasis","volume":"27","author":"Chen","year":"2020","journal-title":"Cell Death Differ."},{"issue":"51","key":"10.1016\/j.biomaterials.2021.121315_bib25","doi-asserted-by":"crossref","first-page":"1904197","DOI":"10.1002\/adma.201904197","article-title":"Recent progress in ferroptosis inducers for cancer therapy","volume":"31","author":"Liang","year":"2019","journal-title":"Adv. Mater."},{"issue":"2","key":"10.1016\/j.biomaterials.2021.121315_bib26","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1039\/D0CS00664E","article-title":"Second near-infrared photothermal materials for combinational nanotheranostics","volume":"50","author":"Xu","year":"2021","journal-title":"Chem. Soc. Rev."},{"issue":"1","key":"10.1016\/j.biomaterials.2021.121315_bib27","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1038\/s41467-021-21047-0","article-title":"Activatable polymer nanoagonist for second near-infrared photothermal immunotherapy of cancer","volume":"12","author":"Jiang","year":"2021","journal-title":"Nat. Commun."},{"issue":"26","key":"10.1016\/j.biomaterials.2021.121315_bib28","doi-asserted-by":"crossref","first-page":"10633","DOI":"10.1002\/anie.202003004","article-title":"Semiconducting polycomplex nanoparticles for photothermal ferrotherapy of cancer","volume":"59","author":"He","year":"2020","journal-title":"Angew. Chem. Int. Ed."},{"issue":"1","key":"10.1016\/j.biomaterials.2021.121315_bib29","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1038\/s41467-019-09221-x","article-title":"Immunostimulatory nanomedicines synergize with checkpoint blockade immunotherapy to eradicate colorectal tumors","volume":"10","author":"Duan","year":"2019","journal-title":"Nat. Commun."},{"issue":"17\u201318","key":"10.1016\/j.biomaterials.2021.121315_bib30","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/j.ccr.2004.12.022","article-title":"The key role of heme to trigger the antimalarial activity of trioxanes","volume":"249","author":"Robert","year":"2005","journal-title":"Coord. Chem. Rev."},{"issue":"1","key":"10.1016\/j.biomaterials.2021.121315_bib31","first-page":"1","article-title":"African-centric TP53 variant increases iron accumulation and bacterial pathogenesis but improves response to malaria toxin","volume":"11","author":"Singh","year":"2020","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.biomaterials.2021.121315_bib32","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1093\/annonc\/mdt118","article-title":"Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia","volume":"24","author":"Ludwig","year":"2013","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.biomaterials.2021.121315_bib33","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nrc3495","article-title":"Iron and cancer: more ore to be mined","volume":"13","author":"Torti","year":"2013","journal-title":"Nat. Rev. Cancer"},{"issue":"40","key":"10.1016\/j.biomaterials.2021.121315_bib34","doi-asserted-by":"crossref","first-page":"14272","DOI":"10.1002\/ange.201907388","article-title":"Programmed release of dihydroartemisinin for synergistic cancer therapy using a CaCO3 mineralized metal\u2013organic framework","volume":"131","author":"Wan","year":"2019","journal-title":"Angew. Chem."},{"issue":"4","key":"10.1016\/j.biomaterials.2021.121315_bib35","doi-asserted-by":"crossref","first-page":"1803791","DOI":"10.1002\/smll.201803791","article-title":"Hydrogen peroxide responsive iron\u2013based nanoplatform for multimodal imaging\u2013guided cancer therapy","volume":"15","author":"Wang","year":"2019","journal-title":"Small"},{"key":"10.1016\/j.biomaterials.2021.121315_bib36","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.biomaterials.2017.09.017","article-title":"Nanomaterials for cancer immunotherapy","volume":"148","author":"Song","year":"2017","journal-title":"Biomaterials"},{"issue":"51","key":"10.1016\/j.biomaterials.2021.121315_bib37","doi-asserted-by":"crossref","first-page":"16686","DOI":"10.1021\/jacs.6b09538","article-title":"Photodynamic therapy mediated by nontoxic core\u2013shell nanoparticles synergizes with immune checkpoint blockade to elicit antitumor immunity and antimetastatic effect on breast cancer","volume":"138","author":"Duan","year":"2016","journal-title":"J. Am. Chem. Soc."},{"issue":"9\u201010","key":"10.1016\/j.biomaterials.2021.121315_bib38","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/smll.201201390","article-title":"Physicochemical characteristics of nanoparticles affect circulation, biodistribution, cellular internalization, and trafficking","volume":"9","author":"Duan","year":"2013","journal-title":"Small"},{"key":"10.1016\/j.biomaterials.2021.121315_bib39","series-title":"Diverse Applications of Nanomedicine","author":"Pelaz","year":"2017"},{"issue":"23","key":"10.1016\/j.biomaterials.2021.121315_bib40","doi-asserted-by":"crossref","first-page":"6492","DOI":"10.1002\/anie.201701181","article-title":"Activatable singlet oxygen generation from lipid hydroperoxide nanoparticles for cancer therapy","volume":"56","author":"Zhou","year":"2017","journal-title":"Angew. Chem. Int. Ed."},{"issue":"13","key":"10.1016\/j.biomaterials.2021.121315_bib41","doi-asserted-by":"crossref","first-page":"9372","DOI":"10.1074\/jbc.M610375200","article-title":"Evidence for the involvement of carbon-centered radicals in the induction of apoptotic cell death by artemisinin compounds","volume":"282","author":"Mercer","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.biomaterials.2021.121315_bib42","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/iub.1895","article-title":"P53\u2010dependent induction of ferroptosis is required for artemether to alleviate carbon tetrachloride\u2010induced liver fibrosis and hepatic stellate cell activation","volume":"71","author":"Wang","year":"2019","journal-title":"IUBMB Life"},{"issue":"6","key":"10.1016\/j.biomaterials.2021.121315_bib43","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/nri2975","article-title":"Mitochondria in innate immune responses","volume":"11","author":"West","year":"2011","journal-title":"Nat. Rev. Immunol."},{"issue":"7","key":"10.1016\/j.biomaterials.2021.121315_bib44","first-page":"1892","article-title":"Nanoscale metal-Organic framework mediates radical therapy to enhance cancer immunotherapy","volume":"5","author":"Ni","year":"2019","journal-title":"Inside Chem."},{"issue":"17","key":"10.1016\/j.biomaterials.2021.121315_bib45","doi-asserted-by":"crossref","first-page":"5678","DOI":"10.1093\/nar\/gkn550","article-title":"\u03b3-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin","volume":"36","author":"Kinner","year":"2008","journal-title":"Nucleic Acids Res."},{"issue":"5","key":"10.1016\/j.biomaterials.2021.121315_bib46","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","article-title":"Ferroptosis: an iron-dependent form of nonapoptotic cell death","volume":"149","author":"Dixon","year":"2012","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.biomaterials.2021.121315_bib47","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.cell.2017.09.021","article-title":"Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease","volume":"171","author":"Stockwell","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.biomaterials.2021.121315_bib48","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20193314","article-title":"Dihydroartemisinin initiates ferroptosis in glioblastoma through GPX4 inhibition","author":"Yi","year":"2020","journal-title":"Biosci. Rep."},{"issue":"7545","key":"10.1016\/j.biomaterials.2021.121315_bib49","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nature14344","article-title":"Ferroptosis as a p53-mediated activity during tumour suppression","volume":"520","author":"Jiang","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.biomaterials.2021.121315_bib50","doi-asserted-by":"crossref","first-page":"14844","DOI":"10.1038\/ncomms14844","article-title":"Inhibiting the system x C\u2212\/glutathione axis selectively targets cancers with mutant-p53 accumulation","volume":"8","author":"Liu","year":"2017","journal-title":"Nat. Commun."},{"issue":"12","key":"10.1016\/j.biomaterials.2021.121315_bib51","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nrc3380","article-title":"Immunogenic cell death and DAMPs in cancer therapy","volume":"12","author":"Krysko","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"10.1016\/j.biomaterials.2021.121315_bib52","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/nri2545","article-title":"Immunogenic and tolerogenic cell death","volume":"9","author":"Green","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.biomaterials.2021.121315_bib53","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic cell death in cancer therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Annu. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.biomaterials.2021.121315_bib54","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nm1523","article-title":"Calreticulin exposure dictates the immunogenicity of cancer cell death","volume":"13","author":"Obeid","year":"2007","journal-title":"Nat. Med."},{"issue":"63","key":"10.1016\/j.biomaterials.2021.121315_bib55","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3001375","article-title":"Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47","volume":"2","author":"Chao","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.biomaterials.2021.121315_bib56","series-title":"Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery","author":"Mosely","year":"2016"}],"container-title":["Biomaterials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961221006712?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0142961221006712?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T17:06:57Z","timestamp":1758906417000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0142961221006712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":56,"alternative-id":["S0142961221006712"],"URL":"https:\/\/doi.org\/10.1016\/j.biomaterials.2021.121315","relation":{},"ISSN":["0142-9612"],"issn-type":[{"value":"0142-9612","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Co-delivery of dihydroartemisinin and pyropheophorbide-iron elicits ferroptosis to potentiate cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Biomaterials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biomaterials.2021.121315","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"121315"}}